Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial

Show full item record



Permalink

http://hdl.handle.net/10138/319347

Citation

HAROSA II Study Grp , Dauvilliers , Y , Verbraecken , J , Partinen , M & Pepin , J-L 2020 , ' Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial ' , American Journal of Respiratory and Critical Care Medicine , vol. 201 , no. 9 , pp. 1135-1145 . https://doi.org/10.1164/rccm.201907-1284OC

Title: Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial
Author: HAROSA II Study Grp; Dauvilliers, Yves; Verbraecken, Johan; Partinen, Markku; Pepin, Jean-Louis
Contributor: University of Helsinki, Department of Neurosciences
Date: 2020-05-01
Language: eng
Number of pages: 11
Belongs to series: American Journal of Respiratory and Critical Care Medicine
ISSN: 1073-449X
URI: http://hdl.handle.net/10138/319347
Abstract: Rationale: Excessive daytime sleepiness is a common disabling symptom in obstructive sleep apnea syndrome. Objectives: To evaluate the efficacy and safety of pitolisant, a selective histamine H3 receptor antagonist with wake-promoting effects, for the treatment of daytime sleepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treatment. Methods: In an international, multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was individually titrated at up to 20 mgld over 12 weeks. The primary endpoint was the change in the Epworth Sleepiness Scale score. Key secondary endpoints were maintenance of wakefulness assessed on the basis of the Oxford Sleep Resistance test, safety, Clinical Global Impression of severity, patient's global opinion, EuroQol quality-of-life questionnaire, and Pichot fatigue questionnaire. Measurements and Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 15.7) were randomized (200 to pitolisant and 68 to placebo) and analyzed on an intention-to-treat basis. The Epworth Sleepiness Scale score was reduced more with pitolisant than with placebo (-2.8; 95% confidence interval, -4.0 to -1.5; P <0.001). Wake maintenance tests were not improved. The Pichot fatigue score was reduced with pitolisant. The overall impact of pitolisant was confirmed by both physicians' and patients' questionnaires. Adverse event incidence, mainly headache, insomnia, nausea, and vertigo, was similar in the pitolisant and placebo groups (29.5% and 25.4%, respectively), with no cardiovascular or other significant safety concerns. Conclusions: Pitolisant significantly reduced self-reported daytime sleepiness and fatigue and improved patient-reported outcomes and physician disease severity assessment in sleepy patients with obstructive sleep apnea refusing or nonadherent to continuous positive airway pressure.
Subject: excessive daytime sleepiness
obstructive sleep apnea
continuous positive airway pressure
pitolisant
RESIDUAL EXCESSIVE SLEEPINESS
IMPORTANT DIFFERENCE
DOUBLE-BLIND
CPAP
OSA
PLACEBO
NARCOLEPSY
MANAGEMENT
MODAFINIL
COGNITION
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
rccm.201907_1284oc.pdf 785.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record